BioLineRx Ltd. Files Form 6-K Reporting Press Release
Ticker: BLRX · Form: 6-K · Filed: Jan 21, 2025 · CIK: 1498403
Sentiment: neutral
Topics: filing, press-release
TL;DR
BioLineRx dropped a 6-K on Jan 21, 2025, likely with news. Check the exhibits for deets.
AI Summary
On January 21, 2025, BioLineRx Ltd. filed a Form 6-K to report the issuance of a press release. The filing itself does not contain the details of the press release, only that it was issued on this date.
Why It Matters
This filing indicates that BioLineRx Ltd. has made a public announcement, the details of which are likely important for investors to understand the company's current status and future outlook.
Risk Assessment
Risk Level: low — This is a routine filing (Form 6-K) that primarily serves to attach a press release, without providing new financial data or significant operational updates within the filing itself.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- January 21, 2025 (date) — Date of press release issuance
- Form 6-K (document) — Type of SEC filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report the issuance of a press release by BioLineRx Ltd. on January 21, 2025.
When was the press release issued by BioLineRx Ltd. that is referenced in this filing?
The press release was issued on January 21, 2025.
What is the Commission file number for BioLineRx Ltd.?
The Commission file number for BioLineRx Ltd. is 001-35223.
Does this Form 6-K contain the full text of the press release?
No, this Form 6-K filing states that the press release is filed as Exhibit 1, implying the details are in an attached exhibit rather than within the main body of the 6-K.
Where is BioLineRx Ltd. headquartered?
BioLineRx Ltd. is headquartered at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2025-01-21 07:11:35
Filing Documents
- zk2532585.htm (6-K) — 8KB
- exhibit_1.htm (EX-99.1) — 21KB
- image0.jpg (GRAPHIC) — 24KB
- image1.jpg (GRAPHIC) — 6KB
- 0001178913-25-000177.txt ( ) — 71KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On January 21, 2025, the Registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: January 21, 2025